Cipher Pharmaceuticals shares soar after $89.5 million Natroba acquisition
Cipher Pharmaceuticals' shares surged 18% to 10.25 Canadian dollars ($7.41) following its $89.5 million acquisition of Natroba's global rights and U.S. operations from ParaPRO.